Ionis Pharmaceuticals (IONS) Receiving Somewhat Positive News Coverage, Accern Reports
News articles about Ionis Pharmaceuticals (NASDAQ:IONS) have trended somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ionis Pharmaceuticals earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.837536920003 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Today’s Research Reports on Stocks to Watch: Ionis Pharmaceuticals and GW Pharmaceuticals (finance.yahoo.com)
- Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : December 4, 2017 (finance.yahoo.com)
- Patrick R. O’neil Sells 1,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock (americanbankingnews.com)
- Ionis Pharmaceuticals, Inc. (IONS) Director Joseph Klein III Sells 3,000 Shares (americanbankingnews.com)
- Elizabeth L. Hougen Sells 6,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock (americanbankingnews.com)
A number of research firms have weighed in on IONS. Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. BMO Capital Markets boosted their price objective on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. Morgan Stanley boosted their price objective on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 8th. Needham & Company LLC reissued a “buy” rating and set a $64.00 price objective on shares of Ionis Pharmaceuticals in a research note on Tuesday, October 17th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $50.00 price objective on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $50.31.
Ionis Pharmaceuticals (NASDAQ:IONS) traded up $0.20 during trading hours on Tuesday, reaching $52.46. The company’s stock had a trading volume of 749,479 shares, compared to its average volume of 1,464,287. Ionis Pharmaceuticals has a 12 month low of $37.26 and a 12 month high of $65.51. The company has a debt-to-equity ratio of 1.50, a current ratio of 6.25 and a quick ratio of 6.21. The stock has a market capitalization of $7,104.61, a P/E ratio of 379.53 and a beta of 2.85.
In other Ionis Pharmaceuticals news, COO B Lynne Parshall sold 16,118 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $65.00, for a total value of $1,047,670.00. Following the sale, the chief operating officer now owns 33,526 shares in the company, valued at $2,179,190. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Elizabeth L. Hougen sold 6,000 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $53.02, for a total value of $318,120.00. Following the completion of the sale, the senior vice president now owns 16,392 shares in the company, valued at approximately $869,103.84. The disclosure for this sale can be found here. Insiders sold 120,886 shares of company stock worth $6,925,315 in the last 90 days. Company insiders own 2.13% of the company’s stock.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.